Arcutis Biotherapeutics, Inc. - 8-K Filing
Arcutis Biotherapeutics reports Q3 2026 ZORYVE revenue of $143.9 million and raises full-year net product sales guidance to $535M–$545M. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits(d) Exhibits)
Tickers: $ARQT
Read the full article at SEC EDGAR
Part of the story ILLINOIS TOOL WORKS INC - 8-K Filing (139 articles)